Origami Therapeutics Analysis: $125K Raised
What is Origami Therapeutics?
Origami Therapeutics is a preclinical-stage biotechnology company developing small-molecule protein degraders and conformation correctors for neurodegenerative diseases. Its ORICISION platform combines chemistry, biology, computational methods, and patient-derived disease models to prioritize compounds that target misfolded proteins, including mutant huntingtin. The company says its approach may address proteins considered undruggable and supports oral, blood-brain-barrier-penetrant candidates.
Location
10210 Campus Point Dr, San Diego, California 92121, United States
Employees
1-10
Founded
2015
Revenue
$1-5M
Product Features & Capabilities
- disease-modifying protein degraders, therapies targeting and degrading disease-related proteins, selective and efficient degradation of disease-causing proteins, small molecules for broad distribution and ease of manufacture, focus on neurodegenerative diseases including Alzheimer's, Huntington's, Parkinson's, Amyotrophic Lateral Sclerosis, Frontotemporal Dementia
How much Origami Therapeutics raised
1: - $125K
2022Lead Investor: Y Combinator
Who are the founders of Origami Therapeutics
BH
Beth Hoffman
Founder
Market Focus
Origami Therapeutics primarily focuses on the biotechnology industry, specifically developing therapies for neurodegenerative diseases such as Alzheimer's, Huntington's, and Parkinson's.
Investors
- Y Combinator
- JLABS
- THE CATALYTIC IMPACT FOUNDATION (CIF)
- California Life Sciences
- U.S. Department of Health and Human Services
- Creative Destruction Lab
Competitors Overview
Origami Therapeutics operates in the neurodegenerative disease treatment market, focusing on developing next-generation therapies that target and degrade disease-related proteins. Its main competitors include:
-
Biogen: Founded in 1978, Biogen is a well-established public company based in Cambridge, Massachusetts. It specializes in therapies for neurodegenerative and immunology disorders. Biogen has raised significant funding (approximately $80 million) and has a strong investor base, giving it a competitive edge in terms of resources and market presence.
-
Denali Therapeutics: Established in 2015 in San Francisco, Denali is also a public company focused on therapies for neurodegenerative diseases. It has raised around $347 million, which allows for extensive research and development capabilities. Denali's focus on innovative treatments positions it as a strong competitor.
-
Annexon: Founded in 2011 and based in San Francisco, Annexon develops antibodies aimed at treating complement-mediated neurodegenerative diseases. With approximately $256 million raised, Annexon has a diverse investor base and a specific focus that differentiates it from Origami.
Notable differences include the scale of funding and the specific focus areas of each competitor. Biogen and Denali have significantly larger funding amounts compared to Origami Therapeutics, which may provide them with more resources for research and development. Additionally, Biogen's long-standing presence in the market gives it a competitive edge in terms of brand recognition and established relationships within the industry.
See something that needs updating? Suggest edits to this profile.